Theralink Technologies Inc.
The Theralink assay combines two well-established technologies:
Laser Capture Microdissection (LCM) and Reverse-Phase Protein
Microarray (RPPA). This combination of technologies, quantifying both the
abundance of total proteins and the activation state of those proteins,
identifies the activated proteins that are the direct targets of cancer
precision medicine therapies. As a result, Theralink can provide
oncologists with a predictive molecular tool aiding in the selection of
appropriate therapies.